Sunovion Pharmaceuticals announced Monday an inhalation powder for the long-term maintenance treatment of airflow obstruction for people with the lung condition known as COPD is now available in the U.S.
The treatment is called the Utibron Neohaler and it is a twice-daily combination long-acting beta agonist and long-acting muscarinic antagonist. Sunovion has the U.S. commercialization rights to the powder, which it obtained through an exclusive license agreement with Novartis late last year. Utibron Neohaler received U.S. Food and Drug Administration approval in October 2015.
The powder proved its effectiveness in clinical studies; it demonstrated significantly improved lung function compared to either of its single bronchodilator components as well as placebo, according to Sunovion.
